TRIal For Efficacy of Capre on hyperTriglyceridemiA

PHASE2CompletedINTERVENTIONAL
Enrollment

387

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

June 30, 2014

Study Completion Date

August 31, 2014

Conditions
Hypertriglyceridemia
Interventions
DRUG

CaPre (TM)

CaPre™ 1.0g + Placebo 1.0g daily for 12 weeks.

OTHER

Placebo

2.0g Placebo (Microcrystalline cellulose) daily for 12 weeks

DRUG

CaPre (TM)

CaPre™ 2.0g daily for 12 weeks

Trial Locations (38)

Unknown

Cardiology Research, Edmonton

Kelowna

Medical Arts Health Research Group, Penticton

St Paul's Hospital, Vancouver

CookMed Research, Victoria

First Line Medical Services Ltd, St. John's

White Hills Medical Clinic, St. John's

Scisco Clinical Research, Cornwall

Corunna Medical Resarch Centre, Corunna

Hamilton Health Sciences, Hamilton

MD-Medical Professional Corporation, Hamilton

Source Unique Research Inc., Hawkesbury

Bagot Street Medical Centre, Kingston

KGK Synergize Inc., London

Milestone Research, London

Robarts Research Institute, London

SPARC, Siebens-Drake Research Institute, London

S & G Clinical Research, Mississauga

SKDA Research Inc., Newmarket

Niagara Falls

Centre Medical Phoenix, Ottawa

University of Ottawa Heart Institute, Ottawa

London Road Diagnostic Clinic and Medical Centre, Sarnia

Sarnia Institute of Clinical Research, Sarnia

Scarborough Cardiology Research, Scarborough Village

Canadian Phase Onward, Toronto

Source Unique Research Inc., Dollard-des-Ormeaux

CLIN DE MED Grand-Mere, Grand-Mère

Diex Research Montreal Inc., Montreal

Institut de recherches cliniques de Montréal (IRCM), Montreal

Royal Victoria Hospital, Montreal

Dynamik Research Inc., Pointe-Claire

Kells Medical Research, Pointe-Claire

Clinique des Maladies Lipidiques de Quebec Inc, Québec

Clinique Médicale St-Louis, Québec

Pro-Recherche Inc., Saint Romuald

Centre médical-des-carrières, Saint-Marc-des-Carrieres

Diex Research Sherbrooke Inc., Sherbrooke

Sponsors
All Listed Sponsors
collaborator

JSS Medical Research Inc.

INDUSTRY

lead

Grace Therapeutics Inc.

INDUSTRY

NCT01455844 - TRIal For Efficacy of Capre on hyperTriglyceridemiA | Biotech Hunter | Biotech Hunter